| Literature DB >> 32111731 |
Zhuo Liu1,2,3,4,5, Liwen Zhu1,6, Zhengjuan Lu1, Huiping Chen1, Lizhen Fan1, Qun Xue7, Jianquan Shi8, Meiying Li9, Hui Li10, Jie Gong11, Jingping Shi12, Tao Wang13, Mei-Ling Jiang1, Runjing Cao1, Hailan Meng1,2,3,4,5, Chenhui Wang14,15, Yun Xu1,2,3,4,5, Cun-Jin Zhang16,2,3,4,5.
Abstract
IL-37 is a newly identified immune-suppressive factor; however, the function, cellular sources, and mechanism of IL-37 in humoral immunity and Myasthenia gravis (MG) are still unclear. In this study, we found IL-37 were substantially downregulated in the serum and PBMCs of MG patients compared with healthy controls. The lower IL-37 was associated with severer disease (quantitative MG score) and higher follicular Th (Tfh)/Tfh17 and B cell numbers. Flow cytometry analysis revealed that IL-37 was mainly produced by CD4+ T cells without overlapping with Th1, Th17, and Tfh subsets in MG patients. Regulatory IL-37+ T cell rarely expressed Foxp3 and CD25 but produced numerous IL-4. Tfh and B cell expressed high levels of SIGIRR, the receptor of IL-37, in MG patients. Mechanically, IL-37 directly bond to SIGIRR, repressed the proliferation, cytokine production of Tfh and B cells, and the secretion of autoantibody via inhibition of STAT3 signaling in Tfh and B cells.Entities:
Year: 2020 PMID: 32111731 DOI: 10.4049/jimmunol.1901176
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422